October 1, 2024
“…UiPath: 212% implied upside… Going forward, Wall Street expects UiPath to grow sales at 10% annually through fiscal 2026 (ends April 2026). That estimate leaves room for upside because the RPA market is forecasted to grow at 40% annually through… Continue Reading…
September 4, 2024
“…COMPASS Pathways (CMPS)… Morgan Stanley analyst Vikram Purohit, who covers the stock, sees CMPS as presenting a compelling risk-reward opportunity. He highlights the company’s leading clinical program… To this end, Purohit rates CMPS shares an Overweight (i.e. Buy), and his $23 price… Continue Reading…
August 27, 2024
https://www.bitchute.com/video/dhFar968Pf3J I got a little behind with the Financial news. When so much happens all at once I get a little behind. I had to watch / catchup with the shows. I linked shared 5 different videos in total. They’re… Continue Reading…
August 14, 2024
“Home prices are being cut at the fastest pace in two years. The share of home listings that saw a price cut rose to 18.9% in July, up 3.4% from last year. Demand is cooling as buyers wait for mortgage… Continue Reading…
August 12, 2024
https://finance.yahoo.com/news/warren-buffetts-selling-over-3-092100064.html While the timing is good lets be honest here. Selling that much stock would cause a flash crash even in a strong economy. At a certain point one has to ask does removing so much money from a sock… Continue Reading…
August 12, 2024
“CervoMed (CRVO) The first Morgan Stanley pick we’ll look at is CervoMed, a clinical-stage medical research firm specializing in neurodegenerative diseases and conditions… Overall, the analyst expects positive clinical results and rates CRVO an Overweight (i.e., Buy). His $35 price… Continue Reading…
August 6, 2024
“…The stock plummeted 26% to $21.48 at the close. It was the second worst day ever for the shares, behind only a 31% drop in July 1974, which was three years after Intel’s IPO. The company’s market cap is now… Continue Reading…
July 31, 2024
“…RegenXBio (RGNX) The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies…. Choi rates RGNX a Buy along with a $38 price target. This… Continue Reading…
July 8, 2024
“Semiconductor company Nvidia (NASDAQ: NVDA) completed a 10-for-1 stock split in June, and fellow chipmaker Broadcom (NASDAQ: AVGO) has a 10-for-1 stock split planned for July. Savvy investors have gravitated toward both stocks. A company’s share price tends to increase about twice as fast as the S&P 500 (SNPINDEX:… Continue Reading…
July 2, 2024
“…Next in the club Which AI companies are in the best position to join these six in the $1 trillion club? My votes go to Broadcom (NASDAQ: AVGO) and Taiwan Semiconductor Manufacturing (NYSE: TSM)… While I predict Broadcom and Taiwan Semiconductor will be the next… Continue Reading…
Recent Comments